Findings from the GLORIA trial suggest that older patients with established rheumatoid arthritis could benefit from 2 years of low-dose glucocorticoids in addition to their existing disease-modifying treatment with a favorable balance of benefit and harm.
The results of two phase 3 studies suggest that dual inhibition of IL-17A and IL-17F with bimekizumab may represent a promising treatment option for nonradiographic axial spondyloarthritis and ankylosing spondylitis.
Philippe Carron comments on the findings from the BE COMPLETE and BE OPTIMAL studies, and discusses how bimekizumab may impact the psoriatic arthritis treatment landscape if approved by the regulatory authorities.
14-06-2022 | EULAR 2022 | Conference coverage | Video
Joseph Merola talks about the BE COMPLETE and BE OPTIMAL trials, which showed that the dual IL-17A/IL-17F inhibitor bimekizumab is a promising treatment option for psoriatic arthritis patients with and without prior exposure to TNF inhibitors.